Zila Nutraceuticals' Ester-C Topical Concentrate to Be Used in Sea & Ski Product Line

PHOENIX--(BUSINESS WIRE)--Sept. 20, 2002--Zila Nutraceuticals (Inter-Cal Nutraceuticals), a division of Zila, Inc. (Nasdaq:ZILA), announced that Sea & Ski, a market leader in sun care products, launched a new core product line containing Ester-C(R) Topical Concentrate, an innovative form of natural vitamin C designed to last in emulsions and penetrate skin layers without chemicals.

The new Sea & Ski Platinum Sunscreen and Skin Care formula was developed for the needs of maturing skin and comes in both SPF 30 and SPF 50 protection.

"The Ester-C ingredient was the best option for Sea & Ski Platinum not only because of its powerful antioxidant qualities, but also because of its stable nature," said Arthur Vallejo, product development manager at Faulding Consumer, Inc., manufacturer of Sea & Ski Suncare. "We use such a high percentage of vitamin C that its regular form would oxidize and brown our product."

The Sea & Ski name has been a recognized brand name in sun care since the 1950s. For more information, visit www.sea-and-ski.com. F.H. Faulding & Co. Limited, manufacturer of drug, health and beauty aids, is Australia's oldest pharmaceutical company and has grown to a global company with offices and affiliations in more than 70 countries.

Zila, Inc., headquartered in Phoenix, Arizona, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units: Zila Pharmaceuticals, marketer of Zilactin(R) oral healthcare products, Peridex(R) prescription mouthrinse and ViziLite(R) oral examination kits, and manufacturer of patented swabs at Innovative Swab Technologies; Zila Nutraceuticals (Inter-Cal Nutraceuticals), manufacturer of patented Ester-C(R) branded products and Palmettx(R) Saw Palmetto; and, Zila BioTechnology, developer of OraTest(R) oral cancer detection products and Zila(R) Tolonium Chloride technologies for cancer and pre-cancer detection and treatment. For more information, visit www.zila.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2001, and Form 10-Q for the quarter ended April 30, 2002, filed with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.